Karolinska Development’s Portfolio Company Anacardio Raises Sek 150 Million To Start Clinical Trial With Candidate Drug Ac01 In Heart Failure

STOCKHOLM, SWEDEN September 7, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has completed a series A investment round of SEK 150 million from a group of long-term and reputable investors, including Flerie Invest, Industrifonden and 3B Health Ventures. The successful financing means a clear external validation of the potential of the company’s drug candidate AC01, which will shortly be evaluated in a clinical phase 1b/2a study in patients with heart failure.